Anti-osteoporotic effects of alisol C 23-acetate via osteoclastogenesis inhibition.

Anti-osteoporotic effects of alisol C 23-acetate via osteoclastogenesis inhibition.
复制标题

C 23-醋酸泽泻醇通过抑制破骨细胞生成发挥抗骨质疏松作用。

DOI:
10.1016/j.biopha.2021.111321
复制
发表时间:
2021-01
影响因子:
7.5
通讯作者:
Wu Shuisheng
Wu Shuisheng
中科院分区:
医学2区
文献类型:
--
作者:
Jia Xiaokang;Zhu Huaichang;Li Gaopan;Lan Mengliu;Li Xiaoyan;Huang Mingqing;Xu Wen;Wu Shuisheng

文献摘要

参考文献

相似文献

泽泻(Alismatis rhizoma,AR)是泽泻(Alisma orientale(Sam.)朱兹(泽泻科)。这种传统的中国配方是利尿,降糖,降血脂。来自AR的Alisol C 23-乙酸酯(AC 23 A)具有抗炎作用并改善某些代谢疾病。然而,AC 23 A减轻骨质疏松症的机制尚不清楚。本研究探讨了AC 23 A在体内和体外的抗肿瘤作用。在卵巢切除(OVX)大鼠模型中,AC 23 A改善OVX诱导的器官系数和骨小梁丢失。在OVX大鼠中,AC 23 A治疗降低血清TRAP 5 b、CTK、β-CTX、TNF-α、IL-6和IL-1β,升高血清E2,并且没有显著改变血清OCN或BALP。AC 23 A在大鼠共培养系统中抑制破骨细胞形成,而不影响成骨细胞活性。RANK(receptor activator of nuclear factor kappaB)信号通道是破骨细胞生成的重要转录元件。AC 23 A抑制RANK配体(RANKL)诱导的TRAP、c-Fos、MMP 9、NFATc 1和CTK表达以及JNK磷酸化。因此,AC 23 A通过抑制RANKL诱导的破骨细胞分化和功能在体外和体内具有抗破骨细胞生成作用。此外,AC 23 A可以通过抑制破骨细胞生成来帮助预防或限制破骨细胞介导的骨疾病。
Alismatis rhizoma (AR) is the dried rhizome ofAlisma orientale(Sam.) Juz. (Alismataceae). This traditional Chinese formula is diuretic, hypoglycemic, and hypolipidemic. Alisol C 23-acetate (AC23A) from AR is anti-inflammatory and ameliorates certain metabolic diseases. However, the mechanism by which AC23A mitigates osteoporosis is unknown. The present study investigated the anti-osteoporotic effects of AC23A in vivo and in vitro. In an ovariectomized (OVX) rat model, AC23A ameliorated OVX-induced organ coefficients and trabecular bone loss. In OVX rats, AC23A treatment lowered serum TRAP5b, CTK, β-CTX, TNF-α, IL-6, and IL-1β, raised serum E2, and did not significantly change serum OCN or BALP. AC23A inhibited osteoclast formation in a rat co-culture system without affecting osteoblast activity. RANK (receptor activator of nuclear factor kappaB) signaling channels are vital osteoclastogenesis transcription elements. AC23A inhibited RANK ligand (RANKL)-induced TRAP, c-Fos, MMP9, NFATc1, and CTK expression and JNK phosphorylation. Therefore, AC23A is anti-osteoclastogenic in vitro and in vivo by inhibiting RANKL-induced osteoclast differentiation and function. Moreover, AC23A could help prevent or limit osteoclast-mediated bone diseases by inhibiting osteoclastogenesis.
传统药物的协同作用如何从网络药理学中受益?
DOI: 10.3390/molecules22071135
发表时间: 2017-07-07
期刊: Molecules (Basel, Switzerland)
影响因子: --
作者:
Yuan H;Ma Q;Cui H;Liu G;Zhao X;Li W;Piao G
通讯作者: Piao G
DOI: 10.1210/edrv.21.2.0395
发表时间: 2000-04
期刊: Endocrine reviews
影响因子: 20.3
作者:
S. Manolagas
通讯作者: S. Manolagas
DOI: 10.3109/s10165-011-0530-8
发表时间: 2012-04
影响因子: 2.2
作者:
I. Nakamura;N. Takahashi;E. Jimi;N. Udagawa;T. Suda
通讯作者: I. Nakamura;N. Takahashi;E. Jimi;N. Udagawa;T. Suda
DOI: 10.1002/jbmr.5650040104
发表时间: 1989-02
影响因子: 6.2
作者:
I. Yamazaki;H. Yamaguchi
通讯作者: I. Yamazaki;H. Yamaguchi
DOI: 10.1182/blood-2010-10-311415
发表时间: 2011-03-31
期刊: BLOOD
影响因子: 20.3
作者:
Sugatani, Toshifumi;Vacher, Jean;Hruska, Keith A.
通讯作者: Hruska, Keith A.